Lilly’s Responsibilities. List all of the materials or information all materials or information that Lilly is required to furnish and actions Lilly is required to take in furtherance of the Project. If there are none, delete this section.
Lilly’s Responsibilities. (i) The activities to be undertaken by Lilly in the course of the Development Program are set forth in the Development Plan, as amended from time to time by the Joint Development Committee and approved by the Steering Committee.
Lilly’s Responsibilities. (i) The activities to be undertaken by Lilly in the course of the Commercialization Program are set forth in the Commercialization Plan, as amended from time to time by the Joint Commercialization Committee and approved by the Steering Committee, and in the Co-Promotion Agreement. Without limiting the generality of the foregoing, Lilly will use Commercially Reasonable Efforts to Commercialize the Product (i) in each Major Market outside the U.S. and (ii) in each country in the Territory outside of the Major Markets that is determined by the JCC to be feasible and commercially attractive for marketing of the Product.
Lilly’s Responsibilities. (i) The activities to be undertaken by LILLY in the course of the Development Program are set forth in the Development Plan attached hereto as Exhibit C, as amended from time to time by the JDC. LILLY will use commercially reasonable efforts, such efforts to be at least equivalent to those efforts that LILLY uses on its own products of similar commercial potential value and at a similar stage of the product life cycle, to develop and obtain Marketing Approval for the Product in all Major Markets and to maximize the commercial value of the Product.
Lilly’s Responsibilities. Lilly shall be responsible for overseeing implementation of the Device Development Plan, addressing fully the appropriate strategy for development and Regulatory Approval of Products, developing the responsibilities of the Parties and the procedures for handling any and all regulatory issues related to Products and Product complaints, determining the Products for which Devices will be developed, and for development of Devices, including clinical development through to the achievement of Regulatory Approval for Product in accordance with the Device Development Plan and for addressing all issues that develop during the course of the Product Development Program, provided that Lilly may request that Antares undertake regulatory aspects of Device development as set forth in this Agreement. With respect to the ***, Lilly will manage, fund, and resource all activities within Lilly and with Third Persons including, but not limited to, working with a Third Person design firm to optimize device ergonomics, functionality, and robustness of the Device, and consult with such Third Person design firm regarding clinical trials, regulatory submissions, and marketing activities. Further, Lilly shall have responsibility for obtaining and maintaining (including, without limitation, satisfying regulatory reporting obligations) all necessary Regulatory Approvals required to conduct the activities contemplated by this Agreement and to commercialize Product. Lilly, or its sublicensees, shall hold legal title to any and all Regulatory Approvals related to the use of Devices in the Field, as well as any equivalents of such items in countries within the Territory. Lilly shall assume full responsibility for the clinical protocols to be developed pursuant to and in support of such applications. ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission.
Lilly’s Responsibilities. B.4.1 If appropriate, the Proposal may describe Lilly's responsibilities to clarify items that are not included in the Services or Deliverables.
